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Chiara Salio1, Adalberto Merighi1 and Rita Bardoni2
Abstract
Presynaptic GABAB receptors (GABABRs) are highly expressed in dorsal root ganglion neurons and spinal cord dorsal horn.
GABABRs located in superficial dorsal horn play an important antinociceptive role, by acting at both pre- and postsynaptic
sites. GABABRs expressed in deep dorsal horn could be involved in the processing of touch sensation and possibly in the
generation of tactile allodynia in chronic pain. The objective of this study was to characterize the morphological and
functional properties of GABABRs expressed on Ab fibers projecting to lamina III/IV and to understand their role in
modulating excitatory synaptic transmission. We performed high-resolution electron microscopic analysis, showing that
GABAB2 subunit is expressed on 71.9% of terminals in rat lamina III-IV. These terminals were engaged in axodendritic
synapses and, for the 46%, also expressed glutamate immunoreactivity. Monosynaptic excitatory postsynaptic currents,
evoked by Ab fiber stimulation and recorded from lamina III/IV neurons in spinal cord slices, were strongly depressed by
application of baclofen (0.1–2.5 mM), acting as a presynaptic modulator. Application of the GABABR antagonist CGP 55845
caused, in a subpopulation of neurons, the potentiation of the first of two excitatory postsynaptic currents recorded with the
paired-pulse protocol, showing that GABABRs are endogenously activated. A decrease in the paired-pulse ratio accompanied
the effect of CGP 55845, implying the involvement of presynaptic GABABRs. CGP 55845 facilitated only the first excitatory
postsynaptic current also during a train of four consecutive stimuli applied to Ab fibers. These results suggest that GABABRs
tonically inhibit glutamate release from Ab fibers at a subset of synapses in deep dorsal horn. This modulation specifically
affects only the early phase of synaptic excitation in lamina III-IV neurons.
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Introduction
The superficial (I-II) and deep (III-IV) laminae of the
dorsal horn of the spinal cord are under strong inhibi-
tory control by the g-aminobutyric acid (GABA).
GABA, the main inhibitory transmitter in the central
nervous system (CNS), modulates neurotransmitter
release and neuronal excitability by acting on two types
of specific receptors referred to as GABAA receptors
(GABAARs) and GABAB receptors (GABABRs) that
may have both pre- and postsynaptic localizations.
In the dorsal horn, GABAARs and GABABRs may be
localized at the level of the primary afferent terminals
originating from the dorsal root ganglion (DRG) neu-
rons, the cell bodies and processes of certain inter-
neurons, and the terminals of descending fibers from
supraspinal centers. Anatomically, the distribution of
GABABRs in these compartments of the dorsal horn
neuropil has been widely investigated,1–8 and function-
ally, it was demonstrated that presynaptic GABABRs
exert an important modulatory role on nociceptive trans-
mission.9 In laminae I-II, electrophysiological studies
performed in rat demonstrated that the exogenous or
endogenous activation of presynaptic GABABRs inhibits
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the release of peptides and glutamate from the primary
afferent terminals of Ad and C types5,10–14 and decreases
the release of GABA and glycine from the spinal inhibi-
tory interneurons.14–16 The depression of neurotransmit-
ter release mediated by GABABRs derives from the
concurrent inhibition of presynaptic calcium chan-
nels17–19 and release machinery downstream Ca2þ entry
into the nerve terminals.20
Investigators paid comparatively little attention to the
contribution of GABABRs to the elaboration of tactile
information in laminae III-IV. In a previous study in rat,
we showed that the synapses between low-threshold mye-
linated A fibers and lamina III/IV neurons are regulated
by endogenous GABA acting on presynaptic GABAARs,
and that these receptors are activated during the repeti-
tive stimulation of the A fibers, thus modulating glutam-
ate release and neuron excitability.21 Our observations
were in line with the notion that the large size DRG
neurons, which give rise to the A fibers, express the
GABAARs at their terminals in laminae III-IV.
22
Notably, GABABRs are also expressed on large diameter
DRG neurons and central terminals of the myelinated A
fibers.5,23 Thus, it seems possible that this family of
GABARs also intervenes in the modulation of mechan-
osensation. In keeping with this possibility, activation of
GABABRs by the specific agonist baclofen depresses the
excitatory postsynaptic currents (EPSCs) evoked by tact-
ile stimuli in vivo.24
By combined morphological and electrophysiological
approaches, we investigated the subcellular localization
and functional properties of the GABABRs expressed on
Ab fibers and their role in modulating the excitability of
lamina III/IV neurons in the rat spinal cord. By record-
ing from an in vitro spinal cord slice preparation, we
show here that presynaptic GABABRs expressed on Ab
fibers are endogenously activated and contribute to
regulate glutamate release during primary afferent
stimulation.
Methods
Animals
The Italian Ministry of Health approved all experiments
that were conducted on young adult rats (P20-P60) in
accordance with the Guide for the Care and Use of
Laboratory Animals and the European Union and
Italian regulations on animal welfare. Three rats were
used for electron microscopy preparations; 70 rats were
employed in electrophysiological experiments.
Electron microscopy
Tissue preparation. After perfusion with glutaraldehyde
(0.1%), formaldehyde (4%), and picric acid (0.2%) in
0.12M sodium phosphate buffer, pH 7.4, spinal cord
blocks were cut in 200 mm transverse sections with a
vibrating blade microtome, and slammed to a polished
copper block cooled with liquid N2 in a MM80E cryo-
fixation apparatus (Reichert, Vienna, Austria). Sections
were then transferred to 0.5% uranyl acetate dissolved in
anhydrous methanol (90C) in a freeze-substitution
apparatus (CS Auto, Leica, Deerfield, IL). The tempera-
ture was raised stepwise to 50C. Samples were finally
infiltrated with Lowicryl HM20 resin (Chemische Werke
Lowi, Waldkraiburg, Germany) and polymerized by
ultraviolet light.25
Primary antibodies and controls. Primary antibodies were
rabbit anti-GABAB2 (1:10; cat. number: ab 75838;
Abcam, Cambridge, UK)26 and mouse anti-glutamate
(1:10, antibodies-online.com, cat. number: 22523;
Atlanta, GA). Routine immunocytochemical controls
consisted in omission of primary antibodies or their sub-
stitution with normal serum.27
Post-embedding electron microscopy. Lowicryl ultrathin sec-
tions were cut with an ultramicrotome (EM UC6; Leica)
and then immunostained on grids following a post-
embedding protocol specifically developed for
Lowicryl-embedded sections.28 All incubations were car-
ried out at room temperature unless otherwise stated.
Sections were first etched with a saturated solution of
NaOH in absolute ethanol for 2–3 s, then rinsed with
double-distilled water. They were then incubated sequen-
tially in the following solutions: (1) 0.1% sodium boro-
hydride and 50mM glycine in Tris buffer (5mM)
containing 0.1% NaCl and 0.1% Triton X-100 (TBNT)
(10min); (2) 2% bovine serum albumin (BSA) in TBNT
(10min); (3) antibodies to glutamate (1:10) and/or
GABAB2 (1:10) in TBNT containing 2% BSA (over-
night); (4) TBNT (several rinses) and 2% BSA in
TBNT (10min); and (5) goat anti-mouse and/or goat
anti-rabbit secondary antibodies coupled to 10 or
20 nm colloidal gold particles (GPs; British BioCell
International, Cardiff, UK), diluted 1:20 in TBNT with
2% BSA and 0.05% polyethylene glycol (2 h). Grids
were then rinsed several times in double-distilled water,
counterstained with uranyl acetate and lead citrate, and
examined with a JEM-1010 transmission electron micro-
scope (Jeol, Tokyo, Japan) equipped with a side-
mounted CCD camera (Mega View III, Olympus Soft
Imaging System, Munster, Germany).
Quantitative immunogold analysis. To assess whether the
GABAB2 subunit was localized at synapses and/or extra-
synaptic sites, counts were performed on 90 randomly
selected ultrathin sections cut across laminae III-IV of
the spinal dorsal horn. The two laminae were first
recognized in toluidine blue-stained semithin sections
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(Figure 1(a)) following the classical description of the
spinal cord cytoarchitectonic organization.29 Then, the
tissue block was trimmed accordingly, and random
images (N¼ 153, n¼ 3 rats) were collected at a magnifi-
cation of 30000. The number of GPs/area (N/m2) over
the synaptic specializations, axon terminals, and den-
drites were calculated using count particle function of
the ImageJ software (NIH, Bethesda, MD). The density
of GPs over mitochondria was chosen as an index of
background staining, and subtracted from values
obtained for the other cellular compartments. GPs
were considered associated with the synaptic specializa-
tions when they were located over the synaptic cleft, the
pre- or the postsynaptic membranes, or at a distance
430 nm from the membrane profiles engaged in the syn-
apse. The distance between the center of each GP and the
center of the synaptic cleft was measured to determine
the distribution of GPs along the pre- or postsynaptic
membrane.28 In this manner, GPs were considered at
pre- or postsynaptic sites when their number on one
side was three-fold higher than on the other side. A syn-
apse was considered immunopositive when at least four
GPs were associated to it according to the criteria
described above.30
Differences in GP densities among individual synaptic
and extrasynaptic compartments at both axon terminals
and dendrites were evaluated with two-way analysis of
variance (ANOVA) test without repeated measures fol-
lowed by Bonferroni multiple comparisons test. Data
were expressed as mean SEM and differences were con-
sidered significant for p< 0.05.
To assess the degree of co-expression between glutam-
ate and GABAB2 in 150 axon terminals, randomly
selected profiles from three rats were directly counted
at the electron microscope. Data were expressed as per-
centages of co-expression.
Electrophysiology
Spinal cord slice preparation. Animals were anesthetized
with isoflurane and decapitated, the spinal cord and ver-
tebrae were rapidly removed and placed in ice-cold dis-
secting Krebs’ solution (composition in mM:125 NaCl,
2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 25 glucose, 6
MgCl2, 1.5 CaCl2, and 1 kynurenic acid, pH 7.4, 320
mOsm), bubbled with 95% O2 and 5% CO2. The
lumbar spinal cord was isolated, embedded in an agarose
block (low-melting point agarose 3%, Thermo Fisher
Figure 1. Topographical identification and examples of synapses in laminae III-IV of the rat dorsal horn: (a) A toluidine blue-stained
semithin section with a black trapezium indicating the area of the dorsal horn, comprising laminae III-IV, subsequently trimmed to cut
ultrathin sections; (b) TEM low magnification of laminae III-IV immunolabeled for GABAB2; and (c) higher magnifications of axosomatic (1),
axodendritic (2), and axo-axonic (3) profiles from the ultrathin section showed in (b). Scale bars: (a) 200mm; (b) and (c) 250 nm.
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Scientific, Waltham, MA), and transverse slices (500mm
thick) were obtained using a vibrating microtome (WPI,
Sarasota, FL). Slices were incubated in oxygenated
Krebs’ solution (same as dissecting but without kynure-
nic acid) at 35C for 1 h and used for recording.
Patch-clamp recording and dorsal root stimulation. Patch-
clamp recording in whole-cell configuration was per-
formed on visually identified lamina III-IV neurons at
room temperature. Neurons were visualized using an
Axioskop microscope (Zeiss, Oberkochen, Germany),
fitted with Nomarski optics and connected to a CCD
camera (Dage-MTI, Michigan City, IN). Lamina
III-IV neurons were identified as being ventral to the
translucent lamina II layer and larger than the lamina
II neurons. All recorded cells were located at a distance
of 200–300 mm from the white matter, corresponding to
the position of laminae III-IV in rat lumbar spinal
cord.31,32 Slices were perfused at 2ml/min with recording
Krebs’ solution (in mM:125 NaCl, 2.5 KCl, 1.25
NaH2PO4, 26 NaHCO3, 25 glucose, 1 MgCl2, and 2
CaCl2, pH 7.4, 320 mOsm). Recordings of EPSCs were
performed in voltage-clamp using thick-walled borosili-
cate pipettes (3–5 MOhm resistance), filled with a solu-
tion having the following composition (in mM): 130
cesium methanesulfonate, 10 sodium methanesulfonate,
10 EGTA, 1 CaCl2, 10 HEPES, 5 lidocaine N-ethyl
bromide quaternary salt-Cl, 2 ATP-Mg, pH adjusted to
7.2 with CsOH, osmolarity 300 mOsm. In order to
isolate the contribution of postsynaptic GABABRs acti-
vated by baclofen, in a subset of experiments the record-
ing pipettes were filled with a potassium-based solution
having the following composition (in mM): 120 potas-
sium methanesulfonate, 10 NaCl, 10 EGTA, 1 CaCl2, 10
HEPES, 5 ATP-Mg, pH adjusted to 7.2 with KOH,
osmolarity 300 mOsm. Junction potential was corrected
after recording. Data were recorded and acquired using a
Multiclamp 700A amplifier and the pClamp 10 software
(Molecular Devices, Sunnyvale, CA). Sampling rate was
10 kHz, and data were filtered at 2 kHz.
The dorsal root attached to each slice was stimulated
using a suction electrode (stimulus intensities: 10–25 mA,
duration: 0.1ms). Monosynaptic EPSCs were
identified by recording 20 consecutive traces at 20Hz.32
Experiments on evoked synaptic responses were per-
formed only on neurons where the EPSC was clearly
visible at each trace and temporally linked to the stimu-
lus artefact. Neurons exhibiting a large polysynaptic
component shunting the subsequent EPSC were not
included in this study.
Drugs, data analysis, and statistics. Drugs were bath applied
for 3–5min. Responses were recorded continuously in
control and during drug application (Figures 3(b)
and 4(b)). Baclofen and CGP 55845 were obtained
from Sigma-Aldrich (St Louis, MO), gabazine
(SR95531) was obtained from Abcam (Cambridge,
UK). Data were analyzed off-line using pClamp10 soft-
ware. Analysis of drug effects on synaptic responses was
performed on EPSCs recorded 2–3min after the start of
drug application. EPSC peak amplitudes were deter-
mined in a constant 2ms window. Mean peak amplitudes
and paired-pulse ratios (PPRs) were calculated from 5–6
averaged traces in the different experimental conditions.
The total charge transfer of EPSCs evoked by a stimu-
lation train of four stimuli was determined by taking the
area under the traces between the baseline time point
immediately before the first EPSC and the time point
at which the fourth EPSC recovered to baseline.
Graphs were obtained using Sigmaplot 11 (Systat
software, San Jose, CA) and statistical analysis was per-
formed using GraphPad (GraphPad software, San
Diego, CA). Data were expressed as mean SEM and
differences were considered significant for p< 0.05.
Results
Expression of GABAB2 subunit in laminae III-IV of
the spinal dorsal horn
We focused our attention on the distribution of the
GABAB2 subunit in laminae III-IV that are easily distin-
guished by the presence of a large number of myelinated
axons and loosely packed neurons of heterogeneous
size, with a prevailing incidence of larger cells than
lamina II.29,33 Laminae III-IV are also characterized by
the prevailing presence of axo-dendritic synapses and less
numerous synapses of the axo-somatic, axo-axonic, and
glomerular types (Figure 1(b) and (c)). Therefore, we
evaluated the relative incidence of GABAB2 in these
types of synapses in the two laminae (Figures 1 and 2).
After observation of 100 randomly selected profiles,
GABAB2 immunoreactivity was localized in 42% (30 of
72) of the axo-dendritic synapses, whereas no labeling
was detected in axo-axonic (N¼ 10) or axo-somatic
(N¼ 15) contacts and in glomeruli (N¼ 3).
Then, after observation of 153 labeled axodendritic
profiles, 49.7% of GABAB2 subunit was distributed
at the presynaptic axonal membrane of the synapse
(Figure 2(a) and (f)), 28.1% at the postsynaptic dendritic
membrane (Figure 2(b) and (f)), and 22.2% at both the
pre- and postsynaptic membranes of the same axoden-
dritic synapse (Figure 2(c) and (f)).
GPs indicative of GABAB2 localization were concen-
trated at synaptic specializations (two-way ANOVA,
p< 0.0001; Bonferroni multiple comparisons test,
p< 0.0001; Figure 2(e)). When both the axon and den-
drite of the same synapse were immunoreactive, there
was not a preferential axonal (presynaptic) or dendritic
(postsynaptic) distribution (two-way ANOVA,
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Figure 2. Localization of GABAB2 at axo-dendritic synapses in laminae III-IV. (a) A GABAB2-immunoreactive At makes a synapse with an
unlabeled dendrite (d). GPs are specifically distributed along the presynaptic membrane (insert number 1). (b) A unlabeled At makes a
synapse with a GABAB2-immunoreactive dendrite (d). GPs are distributed along the postsynaptic density (insert number 2). (c): A GABAB2-
immunoreactive At makes a synapse with a GABAB2-immunoreactive dendrite (d). GPs are scattered over both the pre- and postsynaptic
densities (insert number 3). (d) A glutamateþGABAB2-immunoreactive At makes a synapse with an unlabeled dendrite (d). Glutamate-IR
is characterized by 10 nm GPs, scattered all over the At, while GABAB2 is evidenced by 20 nm GPs specifically distributed along the
presynaptic membrane (insert number 4). (e) Bar chart showing GPs densities (GP/Area, N/m2) at synaptic and extrasynaptic sites of
(At, black bars) and dendrites (D; gray bars).No statistical difference was shown between At and D for both GP/synaptic area (two-way
ANOVA, not repeated measures, p¼ 0.5725) and GP/extrasynaptic area (two-way ANOVA, not repeated measures, p¼ 0.5725). GPs at
the synapse were significantly different from GPs at extrasynaptic sites in both At and D (two-way ANOVA, not repeated measures
followed by Bonferroni multiple comparisons test, ****p< 0.0001). (f) pie chart showing the results of quantitative analysis on the
percentage of expression of GABAB2 at presynaptic sites (black; 49.7%), postsynaptic sites (dark gray; 28.1%), or both (light gray; 22.2%).
Scale bar: 500 nm; inserts: 20 nm.
GABA: g-aminobutyric acid; At: axon terminal; D: dendrite.
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p¼ 0.5725; Figure 2(e)). The few GPs at extrasynaptic
sites were randomly distributed along the membrane of
immunoreactive terminals or dendrites, without signifi-
cant statistical differences between the two compart-
ments (two-way ANOVA, p¼ 0.5752; Figure 2(e)).
Axon terminals expressing GABAB2 contained scat-
tered small agranular vesicles and numerous mitochon-
dria and made simple asymmetric synapses with
dendrites. To better characterize the neurochemistry of
these terminals, we performed double immunogold
Figure 3. The GABAB receptor agonist baclofen depresses the amplitude of evoked EPSCs and increases the PPR in laminae III/IV
neurons. (a) Effect of 1 and 2.5 mM baclofen on EPSCs evoked by Ab fiber stimulation and recorded from a laminae III/IV neuron held at
70mV. The EPSCs were recorded applying the paired-pulse protocol (100ms interval). At each stimulus, baclofen depresses the early,
monosynaptic EPSC and completely suppresses the slower, polysynaptic response. (b) Time course of baclofen effect in the same neuron.
(c) PPR determined from the EPSCs shown in (a), in the different experimental conditions. Both baclofen concentrations increase PPR,
suggesting a presynaptic effect. (d) Intracellular perfusion of the G protein blocker GDP-b-S does not prevent the depressing effect of 1mM
baclofen on evoked EPSCs, recorded from a different laminae III/IV neuron. (e) Dose-dependent effect of baclofen on peak amplitudes of
evoked EPSCs, recorded with the paired-pulse protocol from a total of 45 laminae III/IV neurons. (f) PPR values obtained from the same
EPSCs analyzed in (e), determined in control and in the presence of different concentrations of baclofen. A significant increase of PPR was
observed at each baclofen concentration (paired t-test, p< 0.05 or p< 0.01).
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Figure 4. The endogenous activation of presynaptic GABAB receptors inhibits Ab-fiber-mediated EPSCs. (a) Application of the GABAB
receptor antagonist CGP 55845 (5mM) causes the increase of the first EPSC, recorded with the paired-pulse protocol (averaged EPSCs).
(b) Time course of the effect of 5min application of CGP 55845. (c) The GABAB antagonist produces a decrease of the PPR of the EPSCs
shown in A, indicating a presynaptic effect. (d) Normalized EPSCs amplitudes recorded in a sample of 17 neurons with the paired-pulse
protocol. Red and blue circles represent the EPSC amplitudes (red: first peak and blue: second peak) recorded from the neurons
significantly affected by CGP 55845 (n¼ 6). Light and dark green circles represent the amplitudes of the first and second EPSCs,
respectively, not potentiated by CGP 55845 application (n¼ 11). (e) Mean percentage EPSC amplitude change in the six neurons responsive
to CGP 55845. (f) PPR is significantly decreased by CGP 55845 in the responsive neurons (paired t-test, p< 0.01, n¼ 6). (g) Plot of the PPR
change versus the first EPSC change, obtained from the whole sample of 17 neurons. The negative correlation between the two sets of data
suggests that CGP 55845 causes an increase in release probability in the first EPSC (Pearson product moment correlation test: r¼0.82;
p< 0.001, n¼ 17).
EPSC: excitatory postsynaptic currents; PPR: paired-pulse ratio.
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labeling experiments with a mixture of the glutamate and
GABAB2 antibodies. In these experiments, a large frac-
tion of GABAB2 immunoreactive axons were double
labeled, with GPs indicative of GABAB2 localized at
the synaptic specialization and those depicting glutamate
immunoreactivity scattered all over the axoplasm and
associated with the small agranular synaptic vesicles
herein contained (Figure 2(d)). After observation of
150 GABAB2 (50/animal) randomly selected immunor-
eactive axon terminals, 47.3% were double labeled, 40%
were GABAB2þ only, and 12.7% were glutamateþ only.
Presynaptic GABABRs activated by baclofen modulate
glutamate release from A fibers
In most-recorded laminae III/IV neurons, low-intensity
(10–25 mA) dorsal root stimulation evoked monosynaptic
glutamatergic EPSCs that did not show failures during
high-frequency stimulation (20Hz) and exhibited a
stable latency (latency variability <1ms). These electro-
physiological features were compatible with EPSCs
evoked by Ab fiber stimulation, as shown in previous
studies performed in juvenile rats.32,34 We tested the
effect of the GABAB receptor agonist baclofen on mono-
synaptic EPSCs, recorded with the paired-pulse protocol
(100ms interval). Both 1 and 2.5 mM baclofen rapidly
caused the depression of the two EPSCs (Figure 3(a)
and (b)). As shown in Figure 3(a), baclofen also caused
a marked change in shape of the EPSCs, due to the com-
plete block of the polysynaptic response. This effect was
observed in all neurons exhibiting polysynaptic activity
before baclofen application.
The PPR was determined from the average peak amp-
litudes of the monosynaptic EPSCs, in control and in
presence of baclofen. Since in all tested neurons the
first EPSC was depressed more than the second was,
the value of PPR increased, as expected for a presynaptic
effect (Figure 3(c)).
We tested a total of 35 neurons for different concen-
trations of baclofen, ranging from 0.1 to 2.5 mM: at each
dose, we observed significant depressions of the first
EPSC in all tested neurons (t-test on individual neurons,
p< 0.05, Figure 3(e)) and significant increases of the
PPR value (Figure 3(f)).
Polysynaptic EPSCs evoked by the first stimulus and
overlapping with the second EPSC could cause postsy-
naptic shunting. Thus, the loss of polysynaptic EPSCs in
baclofen could affect the measurement of the second
EPSC and the determination of PPR. However, we did
not find any significant correlation between the ampli-
tude of the first polysynaptic response in control (mea-
sured just before the second stimulus and normalized
by the second peak) and the effect of baclofen on PPR
(baclofen 1 mM, Pearson correlation test, p¼ 0.94,
n¼ 10). This would suggest that changes in postsynaptic
shunting did not significantly contribute to the increase
of PPR by baclofen.
To exclude a contribution of postsynaptic GABABRs
and further confirm the presynaptic nature of the baclo-
fen effect, we performed a separate set of experiments in
which the neurons were intracellularly perfused for
at least 20min with the G protein blocker Guanosine
5’-[beta-thio]diphosphate (GDP-b-S). In these condi-
tions, we tested 1 mM baclofen on the two EPSCs rec-
orded with the paired-pulse protocol (Figure 3(d)),
obtaining values of percentage depression not signifi-
cantly different from those observed in absence of
GDP-b-S (Figure 3(e); t-test, first peak: p¼ 0.85 and
second peak: p¼ 0.76; n¼ 10).
Data represented in Figure 3 were obtained by perfus-
ing the neurons with a cesium-based intracellular solu-
tion. In these conditions, we did not observe a significant
change in the holding current, excluding a substantial
activation of postsynaptic GABABRs. Since postsynap-
tic GABABRs are supposed to act mainly through the
opening of inwardly rectifying potassium channels,35 the
presence of intracellular cesium could have prevented
their activation. Therefore, we tested for baclofen
(1 and 2.5 mM), a group of neurons intracellularly per-
fused with a potassium-based solution. At the holding
potential of 60mV, we recorded an outward current
in 11 out of 12 cells tested (mean current amplitude:
baclofen 1 mM, 24.9 5.9 pA; baclofen 2.5mM,
38.9 10.1 pA), confirming the presence of postsynaptic
GABABRs on laminae III/IV neurons.
Endogenously activated GABABRs regulate synaptic
transmission in laminae III/IV
We then investigatedwhetherGABABRs expressed onAb
fibers could be endogenously activated, by applying the
GABAB antagonist CGP 55845 (5mM) during recording
of evoked EPSCs, and using the paired-pulse protocol. As
shown in Figure 4(a) and (b), CGP 55845 significantly
increased the first EPSC, while the second EPSC was
unchanged (or, in some cases, depressed) and the PPR
value decreased (Figure 4(c)). Since these recordings were
performed using a cesium-based intracellular solution, we
were not able to determine whether CGP 55845 blocked a
tonic current mediated by postsynaptic GABABRs, which
usually involves the activation of potassium channels.
We observed a significant potentiation of the first
EPSC in the presence of CGP 55845 in 6 out of 17 neu-
rons tested (Figure 4(d) and (e); t-test on individual neu-
rons, p< 0.05), accompanied by a significant decrease of
PPR in the responsive neurons (Figure 4(f)). In addition,
the percentage change of PPR was significantly corre-
lated with the variation of the first EPSC (Figure 4(g)),
suggesting that the GABAB antagonist causes an
increase in release probability at the first response.36
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The effect of CGP 55845 on the first EPSC suggested
that GABA tonically activates GABABRs expressed on
Ab fibers, causing a significant depression of glutamate
release at the first stimulus. This could imply that
GABAB presynaptic action is particularly effective
only at the beginning of a stimulation train, as observed
at other central synapses.36 We tested this hypothesis by
repetitively stimulating the dorsal root with a four
pulses train at the frequency of 20Hz. The responses
evoked at the second, third, and fourth stimulus in con-
trol were usually strongly depressed compared to the
first EPSC, as previously reported at this synapse.21
Application of CGP 55845 (5mM) induced a significant
potentiation only of the first EPSC and the decrease of
the PPR value (Figure 5(a) to (c)). The subsequent
three EPSCs were not significantly affected by CGP
55845. In a sample of 13 neurons, we observed a sig-
nificant effect of CGP 55845 on the first EPSCs in five
neurons, with an average increase of 18.9 2.9%
(Figure 5(d); t-test on individual cells, p< 0.05). In all
five responsive neurons, the subsequent peaks were not
significantly changed. High-frequency stimulation trains
produce the temporal summation of the synaptic
responses, that can be monitored through the total
charge transferred along the trains.36 As shown in
Figure 5(e), CGP 55845 failed to induce a significant
change in the total EPSC charge transfer during repeti-
tive stimulation, confirming that GABABRs specifically
affect the initial release events triggered by a stimula-
tion train.
Figure 5. GABABR-mediated presynaptic modulation specifically affects the first EPSC during repetitive stimulation. (a) to (c): Example of
EPSCs recorded from a lamina III/IV neuron, during dorsal root repetitive stimulation (20Hz), in control and in the presence of CGP
55845. Only the first peak is significantly affected by CGP 55845 (b) (t-test performed on samples of eight traces for each condition,
p< 0.05), and the PPR is decreased (c). (d) Normalized EPSC amplitude during the four-pulses train, in control and CGP 55845, obtained
from the five neurons (of 13) where CGP 55845 had a significant effect on the first EPSC. (e) Despite different short-term dynamics, no
relevant difference was observed in EPSC charge transfer between control and CGP 55845 in the same neurons (paired t-test, p¼ 0.26,
n¼ 5).
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We have previously shown that A fibers synapsing
onto laminae III/IV neurons express functional
GABAA receptors, whose activation depresses glutamate
release.21 As observed here for GABABRs, GABAA
receptors were also activated by endogenously released
GABA. Application of gabazine, a GABAA receptor
antagonist, during paired-pulse or repetitive stimulation
of Ab fibers, caused the increase of the second EPSC
recorded from laminae III/IV neurons, leaving the first
EPSC unaffected. This would suggest that although pre-
synaptic GABAARs and GABABRs are both expressed
on Ab fibers, they require different patterns of activation
and exert a different impact on the excitatory synaptic
transmission in deep dorsal horn neurons. To confirm
this hypothesis, we tested the effect of both CGP 55845
(5 mM) and gabazine (10mM) on Ab-mediated EPSCs,
recorded with the paired-pulse protocol. Experiments
performed on 10 laminae III/IV neurons showed that
CGP 55845 potentiates the first EPSC (5/10 neurons),
while gabazine (added to CGP) increases the second
EPSC (6/10 neurons) (Figure 6(a) and (b)). In two neu-
rons, we observed the effects of both CGP 55845
and gabazine, while in the remaining cells only one of
the two antagonists was effective.
In the majority of neurons responsive to gabazine
(4 of 6), we observed a significant increase of the poly-
synaptic responses, revealed by the slower decay of the
EPSCs (Figure 6(a)). Polysynaptic EPSCs evoked by
the first stimulus could potentially cause the shunting
of the second EPSC, affecting its amplitude and the
determination of PPR. However, the percentage increase
of the first polysynaptic response in gabazine was not
significantly correlated with the percentage change of
the second EPSC (Pearson correlation test, p¼ 0.9,
n¼ 6). This is consistent with our previous observation
that the effect of gabazine on the second EPSC is not
significantly affected by postsynaptic shunting.21
Analysis performed on the whole neuron sample con-
firmed that the first EPSC was significantly increased by
CGP 55845 and the second EPSC was significantly
potentiated by gabazine (Figure 6(c)). Both receptor
antagonists act at the presynaptic site, since the PPR
was significantly decreased in CGP 55845 and increased
by adding gabazine (Figure 6(d)).
Discussion
We investigated the GABABRs-mediated inhibition of
Ab fibers synapsing onto laminae III/IV neurons of the
rat spinal cord. First, we demonstrated that presynaptic
GABAB2 is highly expressed at synaptic specializa-
tions of glutamatergic terminals engaged in axo-dendritic
synapses in laminae III-IV (47.3%) Then, we function-
ally showed that the presynaptic GABABRs expressed
on Ab fibers are tonically activated by endogenous
GABA and involved in the modulation of the synaptic
response of laminae III/IV neurons to primary afferent
stimulation. These data suggest that presynaptic
GABABRs could play a relevant role in the processing
of tactile information and the generation of mechanical
allodynia.
GABAB2 immunocytochemical localization as a mean
to label GABABRs in laminae III-IV of spinal cord
The GABABR, as any other member of the class C of the
G protein-coupled receptors, consists of two subunits
referred to as GABAB1 and GABAB2. Both GABAB1
and GABAB2 are essential for the normal function of
GABABRs, following the assembly of heterodimers
made by combinations of the two.37–39 The GABAB1,
in turn, exists in 14 isoforms named from GABAB1a to
GABAB1n
40 GABAB1a and GABAB1b are the most abun-
dant isoforms expressed in the nervous tissue.
By light microscopy immunocytochemistry and in situ
hybridization, it was previously demonstrated that
GABAB1a, GABAB1b, and GABAB2 are all present in
DRG neurons and the spinal cord, where highest expres-
sion occurs in laminae I-III.23,41 In DRGs, GABAB1b
was restricted to the large diameter neurons, in contrast
to GABAB1a (the predominant isoform) and GABAB2,
which were detected in both large and small diam-
eter neurons.23,41 In the spinal cord, GABAB1a and
GABAB2 were localized to the neuropil, whereas
GABAB1b was associated with the neuronal cell
bodies.23 Electron microscopy using an affinity-purified
antibody that recognized the GABAB1a and the
GABAB1b subunits showed that, in laminae I-II,
GABAB1 was localized to myelinated fibers, the central
boutons deriving from unmyelinated primary afferent
fibers in glomeruli, as well as the somato-dendritic
domains of dorsal horn neurons.5
Collectively, these results indicate that: (i) GABAB1b
has a specific somatic localization in spinal cord
and large DRG neurons and is thus not suitable for
localization studies at synapses; (ii) GABAB1a and
GABAB2 are expressed in DRG neurons irrespectively
of size and in the spinal cord neuropil, and are thus
expressed at synapses. As none of the two appears to
have an origin-specific distribution, this leaves open the
possibility that the GABAB2 subunit, which we have here
localized, is expressed in primary afferent terminals as
well as the terminals of descending fibers42 and the
axons/dendrites of the spinal cord neurons. However,
expression of GABAB2 can be considered highly suggest-
ive of a primary afferent origin of the immunoreactive
nerve terminals in the spinal cord neuropil, and staining
for this subunit would, in any case, allow labeling all
synaptic components of the neuropil irrespective of
their origin.
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Localization of functional GABABRs in laminae III/IV
With high-resolution electron microscopy, we here
showed that, in laminae III-IV of the dorsal horn, the
GABAB2 subunit is only detected at axo-dendritic syn-
apses but not at axo-axonic synapses, axo-somatic syn-
apses, or glomeruli. On the light of the discussion above,
lack of GABAB2 immunoreactivity in the primary affer-
ent central boutons of glomeruli was quite unexpected.
However, one has to keep in mind that glomeruli only
represent a minimal fraction of total synapses in the
dorsal horn-about 5% in lamina II, which displays the
highest concentration33 and 3% in our sample.
In GABAB2 immunoreactive axo-dendritic synapses,
the receptor subunit had a prevalent presynaptic
(axonal) localization (about 70%), with a small fraction
of these synapses (about 22%) where GABAB2 was con-
currently detected on the membrane of the postsynaptic
dendrite. On purely theoretical grounds, the spatial reso-
lution of an indirect immunogold labeling procedure
using 20 nm GPs is around 26 nm.43 Therefore, consider-
ing the size of the synaptic cleft (12–20 nm) and the plane
of section at which the synaptic cleft is cut, these data
must be considered with extreme caution, as it is well
possible that we have underestimated the concurrent
presence of pre- or postsynaptic receptors at the same
synapse.
About half of the presynaptic axons expressing
GABAB2 were excitatory, as they contained a variable
number of round, small, clear agranular vesicles,
Figure 6. Comparison between the presynaptic modulations exerted by GABAB and GABAA receptors on the EPSCs evoked by Ab fiber
stimulation. (a) Averaged EPSCs recorded with the paired-pulse protocol, in presence of CGP 55845 (5 mM) and CGP 55845þ gabazine
(10 mM). In this example, CGP 55845 causes the increase in the first EPSC, while gabazine potentiates the second peak. (b) Normalized
EPSC amplitudes obtained from a sample of 10 laminae III/IV neurons, in CGP 55845 and CGP 55845þ gabazine. (c) CGP 55845 causes a
significant change in the first EPSC amplitude (ANOVA, repeated measures, p¼ 0.02, n¼ 10), while gabazine significantly increases the
second peak (ANOVA, repeated measures, p< 0.01, n¼ 10). (d) PPR decreases significantly in CGP 55845, while it increases by adding
gabazine (ANOVA, repeated measures, p¼ 0.02 and 0.002 respectively, n¼ 10).
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numerous mitochondria, made asymmetric axo-dendritic
synapses,29 and were immunolabeled with the anti-gluta-
mate antiserum. Expression of GABABRs in glutamater-
gic terminals is not a new finding, and it was shown that
the cell surface expression of the receptor is independent
of agonist stimulation but controlled by glutamate.44 As
these excitatory GABAB2 immunoreactive axons are
engaged in simple axo-dendritic synapses, they may
have a heterogeneous origin from primary afferent
fibers, or glutamatergic dorsal horn interneurons.
Nonetheless, the electrophysiological experiments,
where the primary afferent Ab fiber release of glutamate
was depressed by the GABABR agonist baclofen with a
presynaptic mechanism, confirmed the primary afferent
origin of at least a fraction of immunoreactive axons
after ultrastructural examination.
In about 28% of GABAB2 immunoreactive synapses,
the receptor subunit was instead (or concurrently)
expressed at the postsynaptic dendrite. This demon-
strates that some spinal cord neurons express GABAB2
at their dendritic domain and suggests that at least some
of these neurons have their cell bodies located in laminae
III-IV. In accordance with ultrastructural data, our elec-
trophysiological recordings, obtained from neurons
intracellularly perfused with a potassium-based solution
in the presence of baclofen, have confirmed the presence
of postsynaptic GABABRs in lamina III/IV neurons.
Finally, it is worth mentioning that it is the GABAB1
subunit that binds baclofen and CGP 55845, which we
have used to activate/inhibit the receptor in electro-
physiological studies, whereas the GABAB2 subunit
only binds positive allosteric modulators.45 Therefore,
our combined structural and functional observations
provide evidence that fully functional receptor heterodi-
mers have pre- and postsynaptic localizations at axo-
dendritic synapses made by Ab fibers and laminae III-
IV neurons.
Functional properties of GABABRs expressed at axo-
dendritic synapses between A fibers and laminae III/
IV neurons
Electrophysiological data and localization studies con-
verged to demonstrate that both pre- and postsynaptic
GABABRs at synapses between Ab fibers and laminae
III/IV neurons were fully functional. The activation of
presynaptic GABABRs by baclofen, in fact, caused a sig-
nificant depression of evoked EPSCs in all tested neu-
rons, accompanied by a change in PPR. Baclofen also
induced an outward current, indicating that postsynaptic
GABABRs were effective in activating a potassium con-
ductance in most recorded neurons.
GABABR-mediated modulation of glutamate release
from primary afferents was described by several electro-
physiological studies, whose findings, however, were
often contradictory. Specifically, while some studies
reported that unmyelinated C fibers were more sensitive
to baclofen than myelinated Ab fibers and that touch-
evoked EPSCs were less inhibited by baclofen than
pinch-evoked EPSCs,13,24 other authors did not observe
any significant difference in baclofen sensitivity between
the fibers mediating different sensory modalities.5,46 In
addition, a recent report showed that the EPSCs,
evoked by optogenetic activation of low threshold,
VGluT3þC fibers and recorded from laminae I-II neu-
rons, were strongly depressed by low (1 mM) baclofen
concentrations.47 Our present data show that Ab fibers
synapsing onto laminae III/IV neurons were indeed
highly sensitive to GABABR activation, since even low
concentrations of baclofen (0.1–0.5 mM) produced sub-
stantial depressions of the evoked EPSCs. Therefore, our
results suggest that GABABRs control a subpopulation
of these synapses under physiological conditions.
The modulation of A fibers is mediated by endo-
genously activated presynaptic GABABRs
At all primary afferent synapses, tested with the paired-
pulse protocol, there was a strong paired-pulse depres-
sion in the absence of any drugs. Blockade of GABABRs
by CGP 55845 induced, in a subpopulation of laminae
III/IV neurons, the facilitation of the first EPSC, accom-
panied by a decrease of PPR. This indicates that the
glutamate release from Ab fibers is endogenously regu-
lated by presynaptic GABABRs at a subpopulation of
synapses in the deep dorsal horn. The fact that the facil-
itating effect of CGP 55845 was visible already at the first
stimulus implies that presynaptic GABABRs were tonic-
ally active. Our results expand what previously observed
in several different areas of the CNS, where GABABRs
are tonically activated by endogenous GABA and regu-
late glutamate release through voltage-gated calcium
channels.14,36,48,49
Since GABABRs have higher affinity for GABA than
GABAARs and their activation requires lower concentra-
tions of neurotransmitter,50 a spillover of GABA from the
synaptic cleft or from the surrounding glial cells might be
sufficient to tonically activate these receptors. Variable
local levels of GABA could explain why only a subpopu-
lation of neurons responded to CGP 55845, despite the
fact that all neurons responded to baclofen. Alternatively,
the different response of laminae III/IV neurons to baclo-
fen and CGP 55845 suggests that baclofen is able to
activate all GABABRs, whereas CGP 55845 only blocks
the synaptic GABABRs activated by endogenously
released GABA.
A number of studies have described the fine structure
of individual axons in laminae III-IV according to spe-
cific sensory modalities. In general, these excitatory
axons are contacted by inhibitory terminals containing
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Figure 7. Schematic summary of the ultrastructural and electrophysiological results obtained in this study. (a) Representation of a
simplified hypothetical circuit compatible with the ultrastructural findings and electrophysiological recordings from rat laminae III/V
neurons. The synaptic organization of the low-threshold A fiber is based on a drawing from Maxwell et al.60 showing that functionally
identified hair follicle afferents receive axo-axonic synapses forming en passant (1) or terminal (2) boutons. These inhibitory terminals can
be recognized as they contain flat or pleomorphic vesicles, form symmetric contacts and are immunoreactive for GABA/glycine. The
GABAB2 subunit is not expressed at these synapses but at the axo-dendritic glutamatergic synapses made by the A fiber onto the laminae
III-IV neurons. These synapses are asymmetric and contain round vesicles labeled with the anti-glutamate antiserum. For simplicity, we have
represented four synapses made by the same fiber impinging onto a patch-clamped laminae III-IV neuron. This recalls the results of
quantitative analysis of immunogold labeling (see text). The scheme also takes in account the quantitative TEM data on GABAB2 subunit-
specific localization at the synaptic specializations. The pre and/or postsynaptic localization of GABAB2 at these synapses is consistent with
the results of patch-clamp experiments. For simplicity, we have not considered the possibility that presynaptic GABAB2 is also expressed
by glutamatergic excitatory interneurons and by glutamate-unreactive axons of (presumptive) descending origin. Both possibilities are
considered in Discussion section.
(b) to (c): Schematic illustration of the presynaptic modulation mediated by GABAA and GABAB receptors expressed on low-threshold A
fiber terminals in dorsal horn laminae III/IV. Synaptic activation of GABAARs causes the depression of the second EPSC during repetitive
stimulation of A fibers (b), while tonic activation of GABABRs by local GABA depresses the first response (c). On the right of each panel,
example traces of evoked EPSCs showing the effect of presynaptic inhibition exerted by GABAARs (blue trace) or GABABRs (red trace).
GABA: g-aminobutyric acid; GABAB2: subunit B2 of the GABA receptor; GABAAR: GABAA receptor; GABABR: GABAB receptor.
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flat or pleiomorphic synaptic vescicles and forming sym-
metric GABAergic/glycinergic synapses.33 Therefore,
one might expect that the GABABRs responsible for
the presynaptic inhibition of glutamate release from Ab
fibers would be located either at the axo-axonic synapses
that these terminals receive from GABAergic/glycinergic
boutons or at extrasynaptic sites in the primary afferent
axonal membrane. However, our ultrastructural data
show that GABAB2 is not expressed at axo-axonic syn-
apses and poorly represented at extrasynaptic sites. As
we have not tried to localize the GABAB1 subunit in our
material, it cannot be excluded that GABAB1 has add-
itional localizations in the neuropil of laminae III-IV. If
so, axo-axonic synapses and/or the extrasynaptic mem-
brane of the primary afferent axons would only express
GABAB1. It is still unclear if these receptors may be
functional in the brain, as a series of observations sug-
gested the possibility that GABAB1 couples to G proteins
also in the absence of GABAB2
45 Thus, an intervention
of GABABRs expressed at axo-axonic synapses or at
extrasynaptic sites cannot be totally ruled out in explain-
ing the effects of baclofen, only if one accepts that
dimers, tetramers, or higher order oligomers only con-
sisting of GABAB1 are fully functional at laminae III-IV
synapses. Figure 7(a) depicts in graphic form a presump-
tive circuit that is compatible with both our ultrastruc-
tural and functional observations.
Recordings performed during repetitive high-fre-
quency (20Hz) stimulation of Ab fibers showed that
only the first response was increased by CGP 55845,
while the subsequent responses were not significantly
affected. Therefore, presynaptic GABABRs on Ab
fibers seem to act specifically on the initial part of the
synaptic response, selectively regulating the onset of exci-
tation in laminae III/IV neurons. Our data are consistent
with studies performed at other central synapses, show-
ing that the GABABR inhibition of evoked glutamate or
GABA release is frequency dependent: during low-fre-
quency trains (0.1–10Hz), GABABRs depressed each
evoked EPSCs or IPSCs, while, at higher frequencies,
they modulated only the first response.36,49 Decrease in
release probability (due to vesicular depletion or other
activity-dependent mechanisms) could prevent an effect-
ive modulation by GABABRs at each stimulus during
high-frequency stimulation. Frequency dependence of
GABABR modulation could also be due to the voltage-
dependent relief of G protein inhibition on calcium
channels during high-frequency firing of presynaptic
neurons.51,52
Functional significance of GABABR-mediated
presynaptic modulation in deep dorsal horn
The data here obtained in the presence of gabazine
confirmed previous results that, during repetitive
stimulation, Ab fibers synapsing onto laminae III/IV
neurons were endogenously modulated by
GABAARs.
21 In that case, only the response to the
second stimulus was depressed, indicating that
GABAARs were not tonically active and that the first
stimulus was necessary to induce GABA release onto
Ab fiber terminals. Figure 7(b) and (c) summarize the
different modalities of activation and the effects of pre-
synaptic GABAARs and GABABRs receptors expressed
on low-threshold A fibers in the deep dorsal horn.
Ab fibers convey the tactile information to laminae
III/IV by firing action potentials at a high frequency
that gradually decreases during the mechanical stimu-
lus, with different adaptation rates. Our data show
that both presynaptic GABAARs and GABABRs tran-
siently inhibit glutamate release from low-threshold
afferents, affecting only the beginning of a train of
afferent action potentials. Therefore, this mechanism
could selectively affect the early phase of the tactile
response, when afferent fibers fire at the highest fre-
quency, by regulating synaptic excitation and action
potential firing.
Besides the role in touch sensation, GABABRs
expressed on Ab fibers could also be involved in the gen-
esis of tactile allodynia, the painful reaction to innocuous
mechanical stimuli observed in pathological pain.
Indeed, in animal models of neuropathic pain, pharma-
cological antagonism of spinal GABABRs produces
mechanical allodynia,53 while intrathecal injection of
baclofen produces anti-allodynic effects.54,55 Moreover,
baclofen decreases the hypersensitivity of dorsal horn
wide dynamic range neurons to low-intensity mechanical
stimulation induced by spinal cord ischemia.56
A decrease in the number, affinity, or coupling of
GABABRs in the deep dorsal horn may underlie the
allodynia occurring in neuropathic pain. As reported
by recent studies, peripheral nerve injury leads to the
decrease of GABABRs expression, both in DRGs
8 and
in the spinal cord dorsal horn,57,58 and to impairment of
the GABAB1/GABAB2 heterodimer assembly.
39,59
Downregulation of GABABRs could decrease the tonic
inhibitory control exerted on low-threshold afferent
fibers, resulting in the increase in the excitatory drive
on laminae III/IV neurons and, ultimately, in allodynia.
In conclusion, our data provide the first ultrastruc-
tural localization of GABABRs in the rat deep dorsal
horn, demonstrate that these receptors are functional
and can be activated by endogenous GABA, and suggest
that, besides mediating some touch-related sensory mod-
alities, they may be involved in the genesis of allodynia
under chronic pain conditions.
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